Unlock instant, AI-driven research and patent intelligence for your innovation.

Antifungal pharmaceutical composition

A technology of antifungal drugs and compositions, applied in the directions of antifungal agents, cyclic peptide components, etc., can solve the problems of liver cell damage, elevated liver enzymes, and high posaconazole, so as to reduce toxic reactions and reduce development. , the effect of reducing fungal resistance

Inactive Publication Date: 2013-10-23
INST OF MICROBIOLOGY - CHINESE ACAD OF SCI
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, posaconazole is expensive, and the treatment is often accompanied by some serious adverse reactions such as bilirubinemia, elevated liver enzymes, liver cell damage, nausea and vomiting, etc.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Antifungal pharmaceutical composition
  • Antifungal pharmaceutical composition

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] Embodiment 1, the interactive antifungal activity test of echinomycin and posaconazole

[0025] The interactive antifungal activity of echinomycin and posaconazole (Candida albicans SC5314) was tested by the checkerboard method. The specific method is:

[0026] Candida albicans SC5314 in RPMI1640 medium, 35°C, humidity 80%, 5% CO 2 Incubate under conditions. Dissolve echinomycin and posaconazole in DMSO to a concentration of 1 mg / mL, and store in a refrigerator until use. To determine the minimum inhibitory concentration (MIC), samples were tested using the two-fold dilution method. Specifically, refer to the National Committee for Clinical Laboratory Standards (NCCLS) M-27A protocol, that is, "Yeast Liquid Medium Dilution Antifungal Drug Susceptibility Test Protocol". Use liquid medium (RPMI1640) to prepare a series of diluted medicinal solutions by 2-fold dilution method, and then Candida albicans SC5314 cells (78 μl, ~1×10 4 ) were inoculated into a 96-well plat...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an antifungal pharmaceutical composition which is composed of A and B, wherein A is selected from at least one of quinoxaline antibiotics, and analogs, derivatives, prodrugs, metabolites and pharmaceutical active salts thereof; and B is selected from at least one of triazole compounds, and analogs, derivatives, prodrugs, metabolites and pharmaceutical active salts thereof. The in-vitro antimicrobial test proves that the combination of posaconazole and echinomycin has strong synergic activity. When the amounts of the posaconazole and echinomycin are respectively reduced by 32-64 times, the posaconazole and echinomycin can still ensure that the test fungi can be 100% cleared in an in-vitro test. The antifungal pharmaceutical composition can provide combined treatment, and is effective for refractory and invasive fungal infections, thereby lowering the amounts of posaconazole, relieving the economic burden of the patient, reducing the toxic reaction of posaconazole and effectively reducing the development of drug tolerance of fungi.

Description

technical field [0001] The invention relates to an antifungal pharmaceutical composition. Background technique [0002] The increasing incidence of fungal infections, especially opportunistic fungal infections in immunocompromised patients, poses a serious challenge to the treatment of fungal infections. Although some fungal drugs have come out one after another, which has brought a new opportunity to the treatment of fungal infections, but at the same time, reports on drug resistance to drug treatment have gradually increased. Therefore, there is a need to develop new antifungal treatments. [0003] Posaconazole is generally used for refractory and invasive fungal infections or other drug-resistant fungal infections. Such infections typically occur in immunocompromised patients, such as those undergoing organ transplants or chemotherapy. Posaconazole was more effective in preventing invasive Aspergillus infection and reduced invasive fungal infection-related mortality co...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K38/12A61P31/10A61K31/496
Inventor 张立新宋福行陈彩霞任彪刘雪婷代焕琴郭徽杨娜
Owner INST OF MICROBIOLOGY - CHINESE ACAD OF SCI